What is true regarding Hurthle cell (HCC) thyroid carcinoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Hürthle Cell Thyroid Carcinoma: Key Clinical Features

The correct answer is C: Hürthle cell carcinoma often metastasizes to cervical lymph nodes, requiring total thyroidectomy with consideration for central neck dissection when lymph nodes are involved. 1, 2

Treatment Requirements (Addressing Option A)

Total thyroidectomy is the standard treatment for Hürthle cell carcinoma, but it is NOT adequate as monotherapy alone. 1 The complete treatment approach includes:

  • Total thyroidectomy is mandatory as the initial surgical procedure, not lobectomy, due to HCC's more aggressive behavior compared to other differentiated thyroid cancers 1
  • Central neck dissection (level VI) is recommended when lymph nodes are positive 1
  • Lateral neck dissection (levels II-IV, consider level V) should be performed if lateral nodes are involved 1, 2, 3
  • TSH suppression therapy with levothyroxine must be administered to all patients postoperatively 1
  • Radioactive iodine ablation should be considered for residual thyroid tissue, though fewer than 10% of HCCs take up radioiodine 1, 3

The statement that total thyroidectomy alone is "adequate" is therefore false—it requires multimodal therapy including hormonal suppression and consideration of RAI ablation. 1, 3

Bilateral Disease Pattern (Addressing Option B)

Option B is FALSE: HCC is frequently bilateral or multifocal, not seldom bilateral. 2

  • HCC commonly presents as bilateral or multifocal disease within the thyroid gland 2
  • While it may present as a solitary nodule initially, the tendency toward multifocality is well-documented 1, 2
  • This multifocal nature is one reason total thyroidectomy is preferred over lobectomy 2

Lymph Node Metastases (Addressing Option C)

Option C is TRUE: HCC often metastasizes to cervical lymph nodes. 2, 3

  • Lymph node metastases are present at surgery in a significant proportion of patients 4, 2
  • HCC is associated with a high rate of locoregional recurrence 2
  • The disease frequently presents with local invasion 2
  • When central or lateral nodes are positive, modified radical neck dissection is indicated 3

This represents a key distinguishing feature requiring aggressive surgical management with lymph node dissection when clinically apparent disease is present. 1, 2

Radiation Association (Addressing Option D)

Option D is FALSE: There is NO established association between HCC and previous neck radiation exposure. 1

  • Unlike papillary thyroid carcinoma, HCC lacks a documented relationship with prior radiation exposure 1
  • In one series, only 1 of 13 patients had a history of childhood head and neck radiation, suggesting no clear causal relationship 4
  • The NCCN guidelines do not list prior radiation as a risk factor specific to HCC 5

Clinical Pearls

Common pitfall: Treating HCC with lobectomy alone leads to inadequate management of this potentially aggressive cancer with multifocal tendencies. 1, 2

Diagnostic limitation: Molecular diagnostics are specifically NOT recommended for Hürthle cell neoplasms due to high false-positive rates (86% unnecessary surgery rate historically). 1

Prognosis consideration: The 10-year relative survival for HCC is approximately 76%, which is lower than papillary (93%) and follicular (85%) carcinomas, reflecting its more aggressive nature. 1

References

Guideline

Hürthle Cell Thyroid Carcinoma Treatment and Characteristics

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Hurthle Cell Carcinoma.

Cancer control : journal of the Moffitt Cancer Center, 1997

Research

Hürthle cell carcinoma.

Current treatment options in oncology, 2001

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.